Barry Quart, Pharm.D.

Barry Quart, Pharm.D.

Former Chief Executive OfficeratHeron Therapeutics, Inc. /De/· In proxies 2022–2023

Pay in FY2023+252% from the year before · Heron Therapeutics, Inc. /De/ stock -32.0% the same year

Barry Quart, Pharm.D. was paid $4.0M in FY2023 (Dec), up 252%. Heron Therapeutics, Inc. /De/ stock fell 32.0% that year.

Pay$100 in the stock at the end of FY21 → $19
Pay is from the Summary Compensation Table of each Heron Therapeutics, Inc. /De/ proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Heron Therapeutics, Inc. /De/Public company · 4 yr
    • Former Chief Executive Officer2022 – Present · 4 yrStock in role -97%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?